{"filing":{"accession_number":"0001213900-26-086393","cik":"0001614744","ticker":"PPBT","company_name":"PURPLE BIOTECH LTD.","form":"6-K","filing_date":"2026-08-07","report_date":"2026-08-07","primary_document":"ea0300940-6k_purple.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1614744/000121390026086393/ea0300940-6k_purple.htm"},"events":[{"id":24976,"run_id":22646,"accession_number":"0001213900-26-086393","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This exhibit is a press release announcing Purple Biotech's second quarter 2026 financial results, including condensed consolidated interim financial statements for the three and six months ended June 30, 2026. The disclosure includes R\u0026D and G\u0026A expenses, operating loss, net income/loss, cash position ($6.1 million), and cash runway through mid-2027. While the company is clinical-stage and pre-revenue, the financial results and cash runway disclosure are material to investors assessing the registrant's financial condition and ability to fund operations.","company_name":"PURPLE BIOTECH LTD.","ticker":"PPBT","filing_date":"2026-08-07","form":"6-K","submitted_at":null,"items":[{"id":25697,"accession_number":"0001213900-26-086393","item_number":"EX-99.1","item_title":"ea030094001ex99-1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a press release announcing Purple Biotech's second quarter 2026 financial results, including condensed consolidated interim financial statements for the three and six months ended June 30, 2026. The disclosure includes R\u0026D and G\u0026A expenses, operating loss, net income/loss, cash position ($6.1 million), and cash runway through mid-2027. While the company is clinical-stage and pre-revenue, the financial results and cash runway disclosure are material to investors assessing the registrant's financial condition and ability to fund operations.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-08T00:01:11.276462+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25697,"accession_number":"0001213900-26-086393","item_number":"EX-99.1","item_title":"ea030094001ex99-1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a press release announcing Purple Biotech's second quarter 2026 financial results, including condensed consolidated interim financial statements for the three and six months ended June 30, 2026. The disclosure includes R\u0026D and G\u0026A expenses, operating loss, net income/loss, cash position ($6.1 million), and cash runway through mid-2027. While the company is clinical-stage and pre-revenue, the financial results and cash runway disclosure are material to investors assessing the registrant's financial condition and ability to fund operations.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-08T00:01:11.276462+00:00","company_name":"PURPLE BIOTECH LTD.","ticker":"PPBT","filing_date":"2026-08-07"},{"id":25698,"accession_number":"0001213900-26-086393","item_number":"EX-99.2","item_title":"ea030094001ex99-2.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is a condensed consolidated unaudited interim financial report for the six months ended June 30, 2026, prepared in accordance with IAS 34 Interim Financial Reporting. It presents complete financial statements (balance sheet, income statement, cash flows, and equity changes) for an interim period, not a discrete event or earnings press release. The document explicitly states it is \"Condensed Consolidated Unaudited Interim Financial Statements as of June 30, 2026\" and should be classified as a periodic interim report deferred for separate processing.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-08T00:01:11.276462+00:00","company_name":"PURPLE BIOTECH LTD.","ticker":"PPBT","filing_date":"2026-08-07"}]}